Wedbush Downgrades Day One Biopharmaceuticals (NASDAQ:DAWN) to Hold

Day One Biopharmaceuticals (NASDAQ:DAWN) was downgraded by stock analysts at Wedbush from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Friday,Zacks.com reports.

Several other equities research analysts have also issued reports on DAWN. TD Cowen lowered Day One Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Friday. Zacks Research downgraded shares of Day One Biopharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. JPMorgan Chase & Co. boosted their price objective on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Finally, JonesTrading lowered shares of Day One Biopharmaceuticals from a “buy” rating to a “hold” rating and increased their price objective for the stock from $20.00 to $21.50 in a research note on Friday. Four research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $25.56.

Day One Biopharmaceuticals Trading Up 65.9%

Shares of NASDAQ:DAWN opened at $21.20 on Friday. The firm has a market cap of $2.19 billion, a PE ratio of -20.58 and a beta of -1.25. The company has a fifty day simple moving average of $11.10 and a 200 day simple moving average of $9.06. Day One Biopharmaceuticals has a 12-month low of $5.64 and a 12-month high of $21.23.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%.The firm had revenue of $53.72 million during the quarter, compared to analyst estimates of $49.81 million. As a group, equities research analysts forecast that Day One Biopharmaceuticals will post -0.72 EPS for the current fiscal year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Adam Dubow sold 6,395 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $74,182.00. Following the sale, the insider owned 72,694 shares in the company, valued at approximately $843,250.40. This trade represents a 8.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Charles N. York II sold 6,065 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $70,354.00. Following the transaction, the chief financial officer owned 312,025 shares of the company’s stock, valued at approximately $3,619,490. This represents a 1.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 36,461 shares of company stock valued at $422,948. Corporate insiders own 6.20% of the company’s stock.

Institutional Trading of Day One Biopharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Day One Biopharmaceuticals by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock valued at $46,000 after purchasing an additional 1,029 shares during the period. Los Angeles Capital Management LLC grew its position in Day One Biopharmaceuticals by 1.4% in the 4th quarter. Los Angeles Capital Management LLC now owns 100,314 shares of the company’s stock valued at $935,000 after buying an additional 1,425 shares in the last quarter. Perkins Capital Management Inc. increased its stake in Day One Biopharmaceuticals by 2.1% during the 4th quarter. Perkins Capital Management Inc. now owns 84,000 shares of the company’s stock valued at $783,000 after buying an additional 1,750 shares during the period. CWM LLC increased its stake in Day One Biopharmaceuticals by 32.4% during the 4th quarter. CWM LLC now owns 8,373 shares of the company’s stock valued at $78,000 after buying an additional 2,051 shares during the period. Finally, ProShare Advisors LLC raised its position in shares of Day One Biopharmaceuticals by 12.9% during the 2nd quarter. ProShare Advisors LLC now owns 18,545 shares of the company’s stock worth $121,000 after buying an additional 2,121 shares in the last quarter. Institutional investors own 87.95% of the company’s stock.

Trending Headlines about Day One Biopharmaceuticals

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Acquisition announced — Servier agreed to buy Day One for $21.50 per share in cash (~$2.5 billion), a deal that crystallizes a takeover premium and explains the sharp rally; the transaction is subject to customary closing conditions and is expected to close in Q2 2026. Article Title
• Positive Sentiment: Analyst target raised — JonesTrading reiterated a “hold” but increased its price target to $21.50 (from $20.00), putting its target in line with the buyout price and reinforcing the deal valuation. Article Title
• Positive Sentiment: Options and volume spike — Unusual call-option activity and extremely high trading volume point to takeover-driven speculative buying and arbitrage interest ahead of the deal close (increased open interest and buy-side activity tend to amplify intraday moves).
• Neutral Sentiment: Trading halt — Shares were temporarily halted earlier for “News pending,” a standard market pause when material corporate announcements are imminent; this is procedural and common around M&A.
• Neutral Sentiment: Ratings reaffirmed — Needham and JonesTrading reaffirmed their “hold” ratings (Needham also maintained its view) even as price targets moved; these keep analyst sentiment mixed despite the takeover. Article Title
• Negative Sentiment: Multiple shareholder investigations and potential litigation — Several law firms (e.g., Brodsky & Smith, Ademi LLP, Halper Sadeh, Monteverde & Associates) announced probes into whether the Board obtained a fair price and followed a proper process; lawsuits or injunctions could delay closing, increase deal costs, or put pressure on the eventual net proceeds to shareholders. Article Title Article Title

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.